TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05937971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plantar sensitivity training
Description: Plantar sensory training protocol:~Applying a moisturizing cream by washing the feet with warm water and drying them (before coming to the session)~Dynamic gastro-soleus stretching (20 sec, 5 reps, 2 min)~Plantar fascia stretch (20 sec, 5 reps, 2 min)~Picking up sheets with feet (10 reps, 2 min)~Pushing the small roller under the foot back and forth (10 reps, 2 min)~Holding the spiny proprioception ball on the plantar surface of the foot while sitting, moving it in anterior-posterior and circular directions (2x2.5 min=5 min)~Keeping the carpet pieces of different softness and texture on the plantar surface of the foot and moving them in anterior-posterior and circular directions (2x2.5 min=5 min) Soft tissue mobilizations applied to the soles of the feet by the physiotherapist (2 minutes)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise training
Description: Warm-up exercises; will consist of stretching exercises (20-30 s, 5 repetitions), breathing exercises (6-10 s, 5 repetitions) and range of motion exercises (8-10 s, 5 repetitions) for the whole body. Conventional exercises will include balance (10 s, 5 reps), coordination (5-10 s, 5 reps), stabilization (5-10 s, 5 reps) and strengthening exercises (8-10 s, 5 reps), specific to each patient. Aerobic exercise training was started at 40% of the maximum heart rate on the treadmill and gradually increased at three-week intervals (40% in weeks 1-3, 50% in weeks 4-6, 60% in weeks 7-9, and 70% in weeks 10-12). ) will be progressed. Cool-down exercises will include a gradual lowering of the treadmill speed (3 min) and ankle range of motion exercises. Plantar sensory training begins with a duration of 5 minutes and progresses from a sitting position to a standing position at three-week intervals (1-3 weeks 5 minutes, 4-6 weeks 10 minutes, 7-9 weeks 15 minutes, 10-12 weeks 20 minutes). will be.
Study: NCT06264947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: wavelength: 808nm energy: 18j power: 100mw

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham laser acupuncture
Description: wavelength: 0nm energy: 0j power: 0mw
Study: NCT05505123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: induction and maintenance with sevoflurane for deep sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: induction and maintenance with propofol for deep sedation
Study: NCT05730140

Intervention type: OTHER
Intervention: this study did not involve interventions; it only observational study
Description: this study did not involve interventions. This study is an observational study for elucidating the intraoperative blood pressure changes, artierial stiffness, and whole exome genome
Study: NCT05937971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise training
Description: Warm-up exercises; will consist of stretching exercises (20-30 s, 5 repetitions), breathing exercises (6-10 s, 5 repetitions) and range of motion exercises (8-10 s, 5 repetitions) for the whole body. Conventional exercises will include balance (10 s, 5 reps), coordination (5-10 s, 5 reps), stabilization (5-10 s, 5 reps) and strengthening exercises (8-10 s, 5 reps), specific to each patient. Aerobic exercise training was started at 40% of the maximum heart rate on the treadmill and gradually increased at three-week intervals (40% in weeks 1-3, 50% in weeks 4-6, 60% in weeks 7-9, and 70% in weeks 10-12). ) will be progressed. Cool-down exercises will include a gradual lowering of the treadmill speed (3 min) and ankle range of motion exercises. Plantar sensory training begins with a duration of 5 minutes and progresses from a sitting position to a standing position at three-week intervals (1-3 weeks 5 minutes, 4-6 weeks 10 minutes, 7-9 weeks 15 minutes, 10-12 weeks 20 minutes). will be.
Study: NCT05107999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zhizhu Kuanzhong capsules (ZZKZ)
Description: FD patients were treated with ZZKZ and omeprazole for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxepin Hydrochloride (Doxepin)
Description: FD patients were treated with doxepin and omeprazole for 4 weeks.
Study: NCT05901441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: For those in SF group: they will be administered with 40 ug/ml sufentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
Study: NCT05147402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midomafetamine
Description: 100 mg midomafetamine (equivalent to 120 mg midomafetamine HCl).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midomafetamine
Description: 100 mg midomafetamine (equivalent to 120 mg midomafetamine HCl).
Study: NCT05921292

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Omeza Products Used in Combination
Description: Subjects in this single-arm study will have the targeted wound/ulcer treated with Omeza® combination therapy which includes the use of the following products:~* Omeza® Lidocaine Lavage~* Omeza® Complete Matrix (OCM™)~* Omeza® Skin Protectant At each treatment (on days 0, 7, 14, 21; +/- 3 days each), the patient's intact skin around the wound/ulcer will be prepped with Omeza® Lidocaine Lavage. OCM™ will be applied directly to the wound/ulcer and Omeza® Skin Protectant will be applied to the periwound and surrounding intact skin. Treatments may be repeated during an optional 7 additional weeks (on days 28, 35, 42, 49, 56, 63, and 70; +/- 3 days each). Final assessment will be made at week 12.
Study: NCT05629221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TreC Diabete App
Description: Participants can download the App from Google Play or Apple Store and activate the App as soon as the clinician provides them a unique activation code, created through an online medical dashboard. The dashboard allows the interaction between healthcare staff and the participant through the use of a chat or a video-chat. Participants are asked to register some information in the App at set times (e.g. blood pressure). Reminders are periodically sent to remember the participants to perform some tasks. Clinicians will periodically check the information entered by the participant (min frequency 45 days).
Study: NCT06314646

Intervention type: PROCEDURE
Intervention: Transanal Transection and Single-Stapled anastomosis (TTSS)
Description: Low anterior rectal resection with Transanal Transection and Single-Stapled anastomosis (TTSS)

Intervention type: PROCEDURE
Intervention: Double-stapled Total Mesorectal Excision (TME)
Description: Low anterior rectal resection with double-stapled Total Mesorectal Excision (TME)
Study: NCT05428605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 10 mL on lithium heparinate tubes, 10 mL on EDTA tubes.
Study: NCT05648201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine 100Mg Tab
Description: 1 single dose of 100mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir 600Mg Tab
Description: 1 single dose of 1200mg taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy 50/200/25 Tab
Description: 1 single dose of 50/200/25 taken orally
Study: NCT06513143

Intervention type: OTHER
Intervention: CT images into virtual 3D model demonstration
Description: The investigators have finished is personalized 3D model translation from CT images into virtual 3D model demonstrated in VR glasses using Synapse.
Study: NCT06302153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Loading Exercises
Description: At start of study, a formal educational session, lasting about 30 minutes will be given by the physiotherapist dealing with the treatment/interventions. Whole treatment plan will be given for six weeks. Pre and post intervention measurements will be taken.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Loading Exercises
Description: At start of study, a formal educational session, lasting about 30 minutes will be given by the physiotherapist dealing with the treatment/interventions. Whole treatment plan will be given for six weeks. Pre and post intervention measurements will be taken.
Study: NCT05172596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHE885
Description: Intravenous (IV) infusion
Study: NCT05662332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Efsitora Alfa
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT05030831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INZ-701
Description: INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
Study: NCT05711485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole blood transfusion
Description: Whole blood is sourced from the Zambia National Blood Transfusion Service.
Study: NCT06261125

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Patients in both cohorts will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 33-48 Gy in 6 fractions over 2 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Patients in both cohorts will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 33-48 Gy in 6 fractions over 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: All patients will reveive adebrelimab 1200 mg every 3 weeks for up to 35 cycles after the completion of SBRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: All patients will reveive adebrelimab 1200 mg every 3 weeks for up to 35 cycles after the completion of SBRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: All patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight \<60 kg) orally once daily after the completion of SBRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: All patients will receive lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight \<60 kg) orally once daily after the completion of SBRT.
Study: NCT06335264

Intervention type: DEVICE
Intervention: Watch HOP
Description: A multisensorial wearable smartwatch that measures actigraphy (motion), skin temperature, heart rate variability (PPG), electrodermal activity, and voice (via App)

Intervention type: DEVICE
Intervention: Watch HOP
Description: A multisensorial wearable smartwatch that measures actigraphy (motion), skin temperature, heart rate variability (PPG), electrodermal activity, and voice (via App)
Study: NCT06525844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regenerative endodontic therapy using I-PRF
Description: Blood will be taken from medial cubital vein

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood clot
Description: Other: BC According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
Study: NCT04845945

Intervention type: BIOLOGICAL
Intervention: PCV15
Description: Blood draw after the vaccination

Intervention type: BIOLOGICAL
Intervention: PCV15
Description: Blood draw after the vaccination
Study: NCT04874402

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prepectoral approach
Description: Two sheets of contour, fenestrated ADM sutured together are trimmed in accordance with the measurement of the expander/implant and fixed to the pectoralis major muscle (superiorly, medially, and inferiorly) and serratus fascia (laterally), covering the entire anterior surface of the device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial Subpectoral approach
Description: The leading edge of the pectoral muscle is elevated and a subpectoral pocket is fashioned. The lower medial origin muscle fibers are released for anatomical expander seating. An ADM sling is sutured from the leading edge of the pectoralis muscle to the inframammary fold (over the expander) and laterally to close the expander pocket. In both groups, the size of the expander and the intraoperative filling volume will be decided by the attending surgeon based on the pocket dimension and volume capabilities.
Study: NCT05035914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
Study: NCT06457074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone Oral Tablet
Description: Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone Oral Tablet
Description: Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).
Study: NCT04421482

Intervention type: OTHER
Group type: OTHER
Intervention: Standard room temperature (RTS) feeding of milk/formula
Description: Evaluate the infant's sucking, swallowing, and breathing patterns using a non-invasive FDA approved equipment (nFant® Feeding Solution) under two separate feeding conditions: standard room temperature (RTS) and cold temperature (CS, at 4-9°C) of milk/formula for an entire feeding (15-20 minutes). The two feedings will be done on the same day but may not necessarily be two consecutive feedings (depending on the baby's eagerness to feed orally). The order of each condition will be randomized to control for fatigue.

Intervention type: OTHER
Group type: OTHER
Intervention: Cold temperature (CS, at 4-9°C) of milk/formula
Description: Evaluate the infant's sucking, swallowing, and breathing patterns using a non-invasive FDA approved equipment (nFant® Feeding Solution) under two separate feeding conditions, standard room temperature (RTS) and cold temperature (CS, at 4-9°C) of milk/formula for an entire feeding (15-20 minutes). The two feedings will be done on the same day but may not necessarily be two consecutive feedings (depending on the baby's eagerness to feed orally). The order of each condition will be randomized to control for fatigue.
Study: NCT06372587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: genetically encoded engineered proteins
Description: using genetically encoded engineered proteins to obtain an inducible control of their activity in living human neurons promoting synaptic plasticity and/or preventing dendritic spines loss

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: genetically encoded engineered proteins
Description: using genetically encoded engineered proteins to obtain an inducible control of their activity in living human neurons promoting synaptic plasticity and/or preventing dendritic spines loss
Study: NCT06257017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1,000 mg/m2 intravenous gemcitabine on day 1 and day 8

Intervention type: DRUG
Group type: OTHER
Intervention: gemcitabine
Description: 1,000 mg/m2 intravenous gemcitabine on day 1 and day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70 mg/m2 intravenous cisplatin (split into 2 doses on day 1 and day 8)

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 70 mg/m2 intravenous cisplatin (split into 2 doses on day 1 and day 8)
Study: NCT05214183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Description: Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab
Study: NCT04409808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRIS
Description: prototype IRIS vitrectomy device.
Study: NCT06178029

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: 20 patients with multiple sclerosis meeting the criteria will undergo conventional rehabilitation and acupuncture treatment.
Study: NCT06527352

Intervention type: DEVICE
Group type: OTHER
Intervention: glottis mask airway
Description: the glottis mask airway is used for maintaining ventilation during general anesthesia

Intervention type: DEVICE
Group type: OTHER
Intervention: glottis mask airway
Description: the glottis mask airway is used for maintaining ventilation during general anesthesia

Intervention type: OTHER
Group type: OTHER
Intervention: tulip shaped
Description: the tulip shaped mask airway is with a tulip shaped tip

Intervention type: OTHER
Group type: OTHER
Intervention: classical shaped
Description: the classical shaped mask airway is with a water-drop shaped tip
Study: NCT04750967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Injectable Solution
Description: Repeated injections of lidocaine to greater occipital nerve and supraorbital nerve once a week for first four weeks then once a month for five months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Amitriptyline 25 mg daily
Study: NCT05700084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule (Part 1)
Description: At least 3 dose cohorts are planned, and 14-26 cases are expected. Cohort 1: 2 cases are planned, and the subjects will receive Utidelone Capsule at a dose of 50 mg/m2/d for 5 days.~Other dose-escalation cohorts: 3-6 cases are planned in each cohort, following the 3 + 3 design. The subjects in these cohorts will receive Utidelone Capsule at 75 mg/m2/d for 5 days, 100 mg/m2/d for 5 days, 100 mg/m2/d for 7 days, and 120 mg/m2/d for 7 days, in a 21-day cycle respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug A Utidelone Capsule (Part 2: Group A-B)
Description: Utidelone Capsule at Part 2 in Group A-B will be administered at 60 mg/m2/d.~At Cycle 0, on day 1, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration).~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration). Subjects will receive the drug on day 1-5 with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug A Utidelone Capsule (Part 2: Group B-A)
Description: Utidelone Capsule at Part 2 in Group B-A will be administered at 60 mg/m2/d.~At Cycle 1, on day 1-5, all patients will receive the drug in fasted status with a glass (approximately 240 ml) of warm water (2 h of fasting before administration; 2 h of fasting after administration), with 21 days as a cycle.~At Cycle 2, subjects will receive the drug after meals on days 1-5 (high-fat meal, drug taken 30 min after the meal; 2 h fasting after administration), with 21 days as a cycle.~For the subsequent treatment period, there is no special requirements for food. Subjects will receive the drug on day 1-5 with 21 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug B Utidelone Injection (Part 2: Group A-B)
Description: Utidelone Injection at Part 2 in Group A-B will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 1, subjects will be administered Utidelone Injection on day 1-5 with 21 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug B Utidelone Injection (Part 2: Group B-A)
Description: Utidelone Injection at Part 2 in Group B-A will be administered at 30 mg/m2/d in 250 mL normal saline, intravenous drip over1.5 h.~For Cycle 0, all patients will be administered Utidelone Injection on day 1, with 21 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals. It is administered continuously for 14 days from day 1 to day 14, with a 21 day treatment cycle.
Study: NCT06178029

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: 20 patients with multiple sclerosis meeting the criteria will undergo conventional rehabilitation
Study: NCT05846490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airway pressure + anti-hypertensive treatment intensification (if necessary)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Anti-hypertensive treatment intensification (if necessary)
Study: NCT05700084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Capsule (Part 3)
Description: Utidelone capsule: 60 mg/m2/d, administered once a day on an empty stomach, continuously for 5 days from day 1 to day 5, with a treatment cycle of 21 days.